Signature Biologics™ Opens Expanded Manufacturing and R&D Headquarters in Irving, TX
PR Newswire | News Releases – Aug 24, 2021, 07:00 ET
IRVING, Texas, Aug. 24, 2021 /PRNewswire/ — Signature Biologics, LLC., today announced their expanded operations footprint to include a new 36,000 sq ft facility in Irving, TX. This newly constructed space mirrors Signature Biologics’ transparency in doing business with open floor plan and floor-to-ceiling views into its fully equipped manufacturing and R&D laboratory spaces. This facility represents the Company’s expansion in operations across perinatal derived tissue, acellular products, and cellular products to fill unmet clinical needs for patients world-wide. [Read More ➔]
Signature Biologics™ Research & Development Staff Published Advanced Findings on COVID-19 and hUC Mesenchymal Stem Cells in Journal of Translational Medicine.
PR Newswire | News Releases – Apr 27, 2021, 07:00 ET
DALLAS, April 27, 2021 /PRNewswire/ — Signature Biologics, LLC., today announced that its research on the immunomodulatory properties of mesenchymal stem cells derived from human umbilical cord (hUC-MSCs) has been published in the Journal of Translational Medicine, “Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells” by Jonathan Hernandez, PhD., et al. Signature Biologics is a regenerative medicine company focused on the development, manufacture, and commercialization of cellular and tissued based products (HCT/P’s) for unmet human medical needs. Dr. Hernandez serves as Vice President of Research and Development to Signature Biologics. [Read More ➔]
Signature Cord Prime™ Receives Investigational New Drug (IND) Approval from FDA for Phase 1 Study in Patients with Symptomatic Osteoarthritis of the Knee.
PR Newswire | News Releases – Feb 16, 2021, 07:00 ET
DALLAS, Feb. 16, 2021 /PRNewswire/ — Signature Biologics, LLC., a regenerative medicine company focused on the development, manufacture, and commercialization of cellular and tissued based products (HCT/P’s) for unmet human medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved an IND Application to proceed with the study of Signature Cord Prime™ in patients with symptomatic osteoarthritis (OA) of the knee with our Principal Investigator. [Read More ➔]